The TROPiCS-02 study: a plain language summary on the effectiveness of sacituzumab govitecan in treating HR-positive/HER2-negative breast cancer
This Plain Language Summary of Publication article (PLSP) from Future Oncology summarises a study called TROPiCS-02 that compared the effectiveness of a medication called sacituzumab govitecan with standard chemotherapy in treating participants with a type of breast cancer called HR-positive/HER2-negative advanced or metastatic breast cancer.
Visit the Future Medicine using the link to read the article.
This PLSP is based on two original articles, the first original article on which this summary is based is called ‘Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer’ and was published in the Journal of Clinical Oncology.
Visit ASCO Publications using the link to read the article.
The second original article on which this summary is based is called ‘Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial’ and was published in the The Lancet.
Visit The Lancet using the link to read the article.